Why PostEra focuses on PCOS

Despite affecting millions of women worldwide, PCOS still has no approved therapies specifically for the condition — leaving many patients managing symptoms without targeted treatment.

In this short video, Alpha Lee, CSO and Co-Founder of PostEra, explains how PostEra is approaching this challenge. The team is targeting AKR1C3, an enzyme linked to androgen excess, starting with hirsutism — one of the most distressing and visible symptoms experienced by many women with PCOS.
The goal: help bring the first targeted, regulatory-approved therapies for PCOS to patients.

Watch the video to hear Alpha’s perspective.